And further. Novo have built a cosy relationship with Jones over the last 3 years (3 Novo related directors now on the CBIO board, 1 of them heavily involved in the licensing agreement 3 years ago while working for Novo).
Novo have had a free ride during this time with CBIO shareholders picking up the tab. If they want the drug they have to pay for it, simple as that. Jones's position is untenable.
Add to My Watchlist
What is My Watchlist?